Archive for May, 2020

  • Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

    GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the…

    by
  • Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

    GOTHENBURG, Sweden, May 14, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the…

    by
  • Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

    GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the…

    by
  • Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

    Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…

    by
  • Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

    GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval…

    by